Loading organizations...
INTA Systems, based in Pisa, Tuscany, Italy, develops portable lab-on-a-chip diagnostic devices utilizing nanoacoustics, nanotechnology, biotechnology, and AI for rapid biosensing in bodily fluids. Its lead product, Nanoanalyzer, targets biomarkers for traumatic brain injuries (TBI), with a Research Use Only version expected in 2025. The company employs 11-20 individuals, generates an estimated annual revenue of $1,112,215, and holds a valuation of $3,600,000. INTA Systems has raised $2,100,000 from investors including Eureka! Fund I, A11 Venture, LIFTT, and Deep Blue Ventures, and opened a new €4 million funding round for medical certification and commercialization. Founded in 2020 by Marco Calderisi, Matteo Agostini, and Marco Cecchini. Its business model centers on raises venture funding to develop and commercialize diagnostic devices, generates estimated revenue from operations.
INTA Systems has raised $2.6M across 3 funding rounds.
INTA Systems has raised $2.6M in total across 3 funding rounds.
INTA Systems has raised $2.6M across 3 funding rounds. Most recently, it raised $2.0M Seed in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2023 | $2M Seed | — | Eureka! Venture | Announced |
| Dec 1, 2022 | $210K Seed | — | Eureka! Venture | Announced |
| Apr 1, 2021 | $420K Seed | — | Eureka! Venture | Announced |
INTA Systems has raised $2.6M in total across 3 funding rounds.
INTA Systems's investors include EUREKA! Venture.
INTA Systems is an Italian deep-tech startup founded in 2020 as the first spin-off from Scuola Normale Superiore and CNR-NANO, specializing in ultrasensitive, portable lab-on-a-chip devices for rapid fluid analysis.[1][3][4] The company develops products like the NanoAnalyser (also called BRAIKER), a coin-sized biosensor that detects biomarkers such as proteins, antibodies, nucleic acids, viruses, and bacteria in minutes using nanoelectronics, biotechnology, and AI, without needing specialized labs.[1][2][3][4][6] It serves healthcare providers, research institutions, clinics, hospitals, and public health organizations, solving critical problems like early traumatic brain injury (TBI) diagnosis from blood droplets, measles detection in saliva, and applications in food analysis, environmental monitoring, security, and industry 4.0.[1][2][3][4] INTA has secured seed funding, including from LIFTT in Q3 2023 (total funding over $2M), achieved prototypes, patents, and industrial collaborations, positioning it for market entry with certifications.[3][4][6]
INTA Systems was founded in April 2020 by Matteo Agostini (PhD in Molecular Biophysics from Scuola Normale Superiore), Marco Cecchini, and Marco Calderisi, emerging as the first joint spin-off from Scuola Normale Superiore di Pisa and CNR-NANO's Nanoscience Institute.[1][3][4] Operating from the NEST laboratory in Pisa, Italy—a hub for nanoscience and nanotechnology—the idea stemmed from integrating condensed-matter physics, nanostructure fabrication, bioconjugation techniques, and AI-driven data analysis to create portable diagnostics.[1][4] Early traction included validating the NanoAnalyser prototype for biomedical use, filing new patents, forming industrial partnerships, and team expansion, with a focus on revolutionizing high-precision, accessible diagnostics.[1][3]
INTA Systems rides the wave of point-of-care diagnostics and personalized medicine, fueled by post-pandemic demand for rapid, decentralized testing amid rising infectious diseases, aging populations, and TBI prevalence.[1][2][4] Timing aligns with advancements in nanoelectronics, AI, and biotech convergence, enabling scalable solutions in a global market prioritizing public health infrastructure, especially in high-burden regions.[2] Market forces like cost pressures on healthcare, regulatory pushes for faster diagnostics, and IoT/sensing growth favor its portable tech, while its spin-off status leverages Italy's research ecosystem for innovation.[1][3] INTA influences the landscape by democratizing ultrasensitive biosensing, potentially cutting diagnostic delays, aiding outbreak control (e.g., measles), and expanding to non-medical sectors like food security.[2][4]
INTA Systems is poised to launch certified devices like BRAIKER/NanoAnalyser into healthcare markets, targeting TBI and infectious disease screening, while scaling to environmental and food applications.[1][3][4] Key trends—AI-enhanced biotech, portable diagnostics boom, and global health equity—will propel growth, with partnerships and data services unlocking revenue beyond hardware.[2][4] Its influence may evolve from niche innovator to ecosystem shaper, driving accessible diagnostics "for everyone, everywhere" and reducing global health burdens through versatile nano-tech.[1] This positions INTA as a high-momentum player in deep-tech biosensing.
